Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma.

Central pathology review system Embryonal rhabdomyosarcoma Low risk Nationwide group study Risk-adopted therapy

Journal

International journal of clinical oncology

ISSN: 1437-7772

Titre abrégé: Int J Clin Oncol

Pays: Japan

ID NLM: 9616295

Informations de publication

Date de publication:
23 Aug 2024

Historique:

received: 04 01 2024

accepted: 04 08 2024

medline: 23 8 2024

pubmed: 23 8 2024

entrez: 23 8 2024

Statut: aheadofprint

Résumé

Failure-free survival (FFS) rates of low-risk patients with rhabdomyosarcoma improved in Intergroup Rhabdomyosarcoma Study IV after the escalation of cyclophosphamide total dose to 26.4 g/m Subgroup-A patients received eight cycles (24 weeks) of vincristine, actinomycin D, and 1.2 g/m In subgroup A (n = 12), the 3-year FFS rate was 83% (95% confidence interval [CI], 48-96), and the 3-year overall survival (OS) rate was 100%. Only one isolated local recurrence was observed (8.3%). There were no unexpected grade-4 toxicities and no deaths. In subgroup B (n = 16), the 3-year FFS and OS rates were 88% (95% CI, 59-97) and 94% (95% CI, 63-99), respectively. There were no unexpected grade 4 toxicities and no deaths. Shorter duration therapy using vincristine, actinomycin D, and lower dose cyclophosphamide with or without radiotherapy for patients with low-risk subgroup A rhabdomyosarcoma (JRS-I LRA0401 protocol) and moderate reduction of cyclophosphamide dose for patients with low-risk subgroup B rhabdomyosarcoma (JRS-I LRB0402 protocol) did not compromise FFS.

Sections du résumé

BACKGROUND BACKGROUND

Failure-free survival (FFS) rates of low-risk patients with rhabdomyosarcoma improved in Intergroup Rhabdomyosarcoma Study IV after the escalation of cyclophosphamide total dose to 26.4 g/m

METHODS METHODS

Subgroup-A patients received eight cycles (24 weeks) of vincristine, actinomycin D, and 1.2 g/m

RESULTS RESULTS

In subgroup A (n = 12), the 3-year FFS rate was 83% (95% confidence interval [CI], 48-96), and the 3-year overall survival (OS) rate was 100%. Only one isolated local recurrence was observed (8.3%). There were no unexpected grade-4 toxicities and no deaths. In subgroup B (n = 16), the 3-year FFS and OS rates were 88% (95% CI, 59-97) and 94% (95% CI, 63-99), respectively. There were no unexpected grade 4 toxicities and no deaths.

CONCLUSIONS CONCLUSIONS

Shorter duration therapy using vincristine, actinomycin D, and lower dose cyclophosphamide with or without radiotherapy for patients with low-risk subgroup A rhabdomyosarcoma (JRS-I LRA0401 protocol) and moderate reduction of cyclophosphamide dose for patients with low-risk subgroup B rhabdomyosarcoma (JRS-I LRB0402 protocol) did not compromise FFS.

Identifiants

DOI: 10.1007/s10147-024-02608-x PMID: 39177879

pubmed: 39177879

doi: 10.1007/s10147-024-02608-x

pii: 10.1007/s10147-024-02608-x

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : Japan Agency for Medical Research and Development

ID : JP19ck0106333

Organisme : Japan Agency for Medical Research and Development

ID : JP20ck0106610

Informations de copyright

Références

Raney RB, Anderson JR, Barr FG et al (2001) Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 23:215–220

doi: 10.1097/00043426-200105000-00008 pubmed: 11846299

Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 59:5–10

doi: 10.1002/pbc.24118 pubmed: 22378628 pmcid: 4008325

Hosoi H (2016) Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan. Pediatr Int 58:81–87

doi: 10.1111/ped.12867 pubmed: 26646016

Lawrence W, Gehan EA, Hays DM et al (1987) Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 5:46–54

doi: 10.1200/JCO.1987.5.1.46 pubmed: 3543238

Lawrence W, Anderson JR, Gehan EA et al (1997) Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children’s Cancer Study Group. Pediatric Oncology Group. Cancer 80:1165–1170

doi: 10.1002/(SICI)1097-0142(19970915)80:6<1165::AID-CNCR21>3.0.CO;2-5 pubmed: 9305719

Arndt CA (2013) Risk stratification of rhabdomyosarcoma: a moving target. American Society of Clinical Oncology educational book. American Society of Clinical Oncology, Alexandria, pp 415–419

Weiss AR, Lyden ER, Anderson JR et al (2013) Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 31:3226–3232

doi: 10.1200/JCO.2012.44.6476 pubmed: 23940218 pmcid: 3757291

Crist WM, Gehan EA, Ragab AH et al (1995) The third intergroup rhabdomyosarcoma study. J Clin Oncol 13:610–630

doi: 10.1200/JCO.1995.13.3.610 pubmed: 7884423

Crist WM, Anderson JR, Meza JL et al (2001) Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19:3091–3102

doi: 10.1200/JCO.2001.19.12.3091 pubmed: 11408506

Baker KS, Anderson JR, Link MP et al (2000) Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: Results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 18:2427–2434

doi: 10.1200/JCO.2000.18.12.2427 pubmed: 10856103

Ortega JA, Donaldson SS, Ivy SP et al (1997) Veno-occlusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Children’s Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Cancer 79:2435–2439

doi: 10.1002/(SICI)1097-0142(19970615)79:12<2435::AID-CNCR21>3.0.CO;2-R pubmed: 9191535

Kenney LB, Laufer MR, Grant FD et al (2001) High risk of infertility and long-term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 91:613–621

doi: 10.1002/1097-0142(20010201)91:3<613::AID-CNCR1042>3.0.CO;2-R pubmed: 11169946

Green DM, Liu W, Kutteh WH et al (2014) Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol 15:1215–1223

doi: 10.1016/S1470-2045(14)70408-5 pubmed: 25239573 pmcid: 4192599

Chiarelli AM, Marrett LD, Darlington G (1999) Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964–1988 in Ontario, Canada. Am J Epidemiol 150:245–254

doi: 10.1093/oxfordjournals.aje.a009995 pubmed: 10430228

Barton SE, Najita JS, Ginsburg ES et al (2013) Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 14:873–881

doi: 10.1016/S1470-2045(13)70251-1 pubmed: 23856401

Flamant F, Rodary C, Rey A et al (1988) Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 34:1050–1062

doi: 10.1016/S0959-8049(98)00024-0

Koscielniak E, Harms D, Henze G et al (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17:3706–3719

doi: 10.1200/JCO.1999.17.12.3706 pubmed: 10577842

Walterhouse DO, Pappo AS, Meza JS et al (2014) Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 32:3547–3552

doi: 10.1200/JCO.2014.55.6787 pubmed: 25267746 pmcid: 4209105

Walterhouse DO, Pappo AS, Meza JL et al (2017) Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Cancer 123:2368–2375

doi: 10.1002/cncr.30613 pubmed: 28211936

Hosoi H, Teramukai S, Matsumoto Y et al (2007) A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol 12:137–145

doi: 10.1007/s10147-006-0638-6 pubmed: 17443282

Newton WA Jr, Gehan EA, Webber BL et al (1995) Classification of rhabdomyosarcoma and related sarcomas. Pathologic aspects and proposals for a new classification—an intergroup rhabdomyosarcoma study. Cancer 76:1073–1085

doi: 10.1002/1097-0142(19950915)76:6<1073::AID-CNCR2820760624>3.0.CO;2-L pubmed: 8625211

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

doi: 10.1093/jnci/92.3.205 pubmed: 10655437

Arndt C, Hawkins D, Anderson JR et al (2004) Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 22:1895–1901

doi: 10.1200/JCO.2004.08.075

Raney RB, Walterhouse DO, Meza JL et al (2011) Results of the intergroup rhabdomyosarcoma study group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 29:1312–1318

doi: 10.1200/JCO.2010.30.4469 pubmed: 21357783

Breneman J, Meza J, Donaldson SS et al (2012) Local control with reduced dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children’s Oncology Group D9602 study. Int J Radiat Oncol Biol Phys 83:720–726

doi: 10.1016/j.ijrobp.2011.06.2011 pubmed: 22104356

Russell H, Swint JM, Lal L et al (2014) Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: a report from the Children’s Oncology Group. Pediatr Blood Cancer 61:970–976

doi: 10.1002/pbc.24950 pubmed: 24453105 pmcid: 4370185

Walterhouse DO, Meza JL, Breneman JC et al (2011) Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children’s Oncology Group. Pediatr Blood Cancer 57:76–83

doi: 10.1002/pbc.22928 pubmed: 21298768 pmcid: 3459820

Miyachi M, Tsuchiya K, Hosono A et al (2019) Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: a study protocol. Medicine 98:e18344

doi: 10.1097/MD.0000000000018344 pubmed: 31876708 pmcid: 6946342

Wyatt KD, Birz S, Hawkins DS (2022) Creating a data commons: the international soft tissue sarcoma consortium (INSTRuCT). Pediatr Blood Cancer 69:e29924

doi: 10.1002/pbc.29924 pubmed: 35969120 pmcid: 9560864